Prelude Therapeutics (PRLD) Non-Current Assets (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Non-Current Assets data on file, last reported at $35.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 9.8% year-over-year to $35.0 million; the trailing twelve-month figure through Mar 2026 stood at $145.1 million (down 9.79% YoY), and the FY2025 full-year result was $35.6 million, down 10.09% from the prior year.
• Non-Current Assets eased to $35.0 million in Q1 2026, from $35.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $42.1 million in Q4 2023 to a low of $10.4 million in Q2 2022.
• A 5-year average of $30.0 million and a median of $35.6 million in 2025 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets surged 190.11% in 2022 and fell 10.8% in 2025, its largest moves.
• Tracing PRLD's Non-Current Assets over 5 years: stood at $16.1 million in 2022, then jumped by 161.02% to $42.1 million in 2023, then slipped by 5.84% to $39.6 million in 2024, then retreated by 10.09% to $35.6 million in 2025, then dropped by 1.61% to $35.0 million in 2026.
• Business Quant data shows PRLD's Non-Current Assets at $35.0 million in Q1 2026, $35.6 million in Q4 2025, and $36.4 million in Q3 2025.